Carlson Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

Carlson Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-71,561	Closed	-$9.64M	–	261
2017 Q4	$9.64M	Buy	+71,561	New	+$9.93M	0.16%	169
2017 Q2	–	Sell	-150,037	Closed	-$21.8M	–	274
2017 Q1	$21.8M	Sell	150,037 -225,921	-60%	-$29.4M	0.28%	116
2016 Q4	$41M	Buy	375,958 +298,240	+384%	+$33.2M	0.49%	60
2016 Q3	$9.44M	Sell	77,718 -50,007	-39%	-$6.74M	0.12%	189
2016 Q2	$18M	Buy	+127,725	New	+$18.8M	0.22%	137

Other funds holding JAZZ

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

SIG

Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Carlson Capital's JAZZ Position: Q1 2018 in Review

Carlson Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2018, closing a stake of 71,561 shares — an estimated $9.64M sold.

Carlson Capital first reported a position in JAZZ in Q2 2016 and held it in 5 quarters. The position peaked at $41M in Q4 2016. 323 funds tracked by Wall St. Rank hold JAZZ as of Q1 2018.

Carlson Capital reported no remaining Jazz Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Carlson Capital sold 71,561 Jazz Pharmaceuticals shares in Q1 2018, an estimated $9.64M.
Carlson Capital first reported a position in Jazz Pharmaceuticals in Q2 2016 and held it in 5 quarters.
Carlson Capital's Jazz Pharmaceuticals position peaked at $41M in Q4 2016.
323 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2018.

Based on Carlson Capital's 13F filing for Q1 2018, filed 15 May 2018.